These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
142 related articles for article (PubMed ID: 29441509)
1. NRF2, DJ1 and SNRX1 and their prognostic impact in astrocytic gliomas. Haapasalo J; Nordfors K; Granberg KJ; Kivioja T; Nykter M; Haapasalo H; Soini Y Histol Histopathol; 2018 Aug; 33(8):791-801. PubMed ID: 29441509 [TBL] [Abstract][Full Text] [Related]
2. Nuclear factor erythroid-derived 2-like 2 (Nrf2) and DJ1 are prognostic factors in lung cancer. Merikallio H; Pääkkö P; Kinnula VL; Harju T; Soini Y Hum Pathol; 2012 Apr; 43(4):577-84. PubMed ID: 21943684 [TBL] [Abstract][Full Text] [Related]
3. Nuclear Nrf2 expression is related to a poor survival in pancreatic adenocarcinoma. Soini Y; Eskelinen M; Juvonen P; Kärjä V; Haapasaari KM; Saarela A; Karihtala P Pathol Res Pract; 2014 Jan; 210(1):35-9. PubMed ID: 24189098 [TBL] [Abstract][Full Text] [Related]
4. Phosphorylated Hsp27 is mutually exclusive with ATRX loss and the IDH1 Cai HQ; Wang PF; Zhang HP; Cheng ZJ; Li SW; He J; Zhang Y; Hao JJ; Wang MR; Yan CX; Wan JH J Clin Pathol; 2018 Aug; 71(8):702-707. PubMed ID: 29550762 [TBL] [Abstract][Full Text] [Related]
5. Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas. Hartmann C; Hentschel B; Wick W; Capper D; Felsberg J; Simon M; Westphal M; Schackert G; Meyermann R; Pietsch T; Reifenberger G; Weller M; Loeffler M; von Deimling A Acta Neuropathol; 2010 Dec; 120(6):707-18. PubMed ID: 21088844 [TBL] [Abstract][Full Text] [Related]
6. PROX1 is a novel pathway-specific prognostic biomarker for high-grade astrocytomas; results from independent glioblastoma cohorts stratified by age and IDH mutation status. Roodakker KR; Elsir T; Edqvist PD; Hägerstrand D; Carlson J; Lysiak M; Henriksson R; Pontén F; Rosell J; Söderkvist P; Stupp R; Tchougounova E; Nistér M; Malmström A; Smits A Oncotarget; 2016 Nov; 7(45):72431-72442. PubMed ID: 27626492 [TBL] [Abstract][Full Text] [Related]
7. Nuclear karyopherin a2: a novel biomarker for infiltrative astrocytomas. Gousias K; Becker AJ; Simon M; Niehusmann P J Neurooncol; 2012 Sep; 109(3):545-53. PubMed ID: 22772608 [TBL] [Abstract][Full Text] [Related]
8. Hsp27 and its expression pattern in diffusely infiltrating astrocytomas. Mäkelä KS; Haapasalo JA; Ilvesaro JM; Parkkila S; Paavonen T; Haapasalo HK Histol Histopathol; 2014 Sep; 29(9):1161-8. PubMed ID: 24599602 [TBL] [Abstract][Full Text] [Related]
9. WT1 expression increases with malignancy and indicates unfavourable outcome in astrocytoma. Rauscher J; Beschorner R; Gierke M; Bisdas S; Braun C; Ebner FH; Schittenhelm J J Clin Pathol; 2014 Jul; 67(7):556-61. PubMed ID: 24607494 [TBL] [Abstract][Full Text] [Related]
10. Utility of methylthioadenosine phosphorylase immunohistochemical deficiency as a surrogate for CDKN2A homozygous deletion in the assessment of adult-type infiltrating astrocytoma. Satomi K; Ohno M; Matsushita Y; Takahashi M; Miyakita Y; Narita Y; Ichimura K; Yoshida A Mod Pathol; 2021 Apr; 34(4):688-700. PubMed ID: 33077924 [TBL] [Abstract][Full Text] [Related]
11. In vivo Metabolic Profiles as Determined by Wenger KJ; Hattingen E; Franz K; Steinbach J; Bähr O; Pilatus U Clin Neuroradiol; 2019 Mar; 29(1):27-36. PubMed ID: 28983683 [TBL] [Abstract][Full Text] [Related]
12. High CHI3L1 expression is associated with glioma patient survival. Steponaitis G; Skiriutė D; Kazlauskas A; Golubickaitė I; Stakaitis R; Tamašauskas A; Vaitkienė P Diagn Pathol; 2016 Apr; 11():42. PubMed ID: 27121858 [TBL] [Abstract][Full Text] [Related]
13. Genetic polymorphisms and protein expression of NRF2 and Sulfiredoxin predict survival outcomes in breast cancer. Hartikainen JM; Tengström M; Kosma VM; Kinnula VL; Mannermaa A; Soini Y Cancer Res; 2012 Nov; 72(21):5537-46. PubMed ID: 22964583 [TBL] [Abstract][Full Text] [Related]
14. IDH1 mutation can be present in diffuse astrocytomas and giant cell glioblastomas of young children under 10 years of age. Ferris SP; Goode B; Joseph NM; Kline CN; Samuel D; Gupta N; Bollen A; Perry A; Mueller S; Solomon DA Acta Neuropathol; 2016 Jul; 132(1):153-5. PubMed ID: 27161253 [No Abstract] [Full Text] [Related]
15. WT1 Clone 6F-H2 Cytoplasmic Expression Differentiates Astrocytic Tumors from Astrogliosis and Associates with Tumor Grade, Histopathology, IDH1 Status, Apoptotic and Proliferative Indices: A Tissue Microarray Study. Abd El-Hafez A; Ismail Hany HSED Asian Pac J Cancer Prev; 2020 Aug; 21(8):2403-2413. PubMed ID: 32856872 [TBL] [Abstract][Full Text] [Related]
16. IDH mutation, 1p19q codeletion and ATRX loss in WHO grade II gliomas. Leeper HE; Caron AA; Decker PA; Jenkins RB; Lachance DH; Giannini C Oncotarget; 2015 Oct; 6(30):30295-305. PubMed ID: 26210286 [TBL] [Abstract][Full Text] [Related]
18. Prognostic value of survivin and DNA topoisomerase IIα in diffuse and anaplastic astrocytomas. Varughese RK; Skjulsvik AJ; Torp SH Pathol Res Pract; 2017 Apr; 213(4):339-347. PubMed ID: 28214203 [TBL] [Abstract][Full Text] [Related]
19. DMBT1 homozygous deletion in diffuse astrocytomas is associated with unfavorable clinical outcome. Motomura K; Mittelbronn M; Paulus W; Brokinkel B; Keyvani K; Sure U; Wrede K; Nakazato Y; Tanaka Y; Pierscianek D; Kim YH; Mariani L; Vital A; Ohgaki H J Neuropathol Exp Neurol; 2012 Aug; 71(8):702-7. PubMed ID: 22805772 [TBL] [Abstract][Full Text] [Related]
20. Loss of ATRX, associated with DNA methylation pattern of chromosome end, impacted biological behaviors of astrocytic tumors. Cai J; Chen J; Zhang W; Yang P; Zhang C; Li M; Yao K; Wang H; Li Q; Jiang C; Jiang T Oncotarget; 2015 Jul; 6(20):18105-15. PubMed ID: 25971279 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]